6 November 2023 - As drugs demonstrating superior efficacy over existing standard treatments for blood cancers repeatedly failed to get insurance benefits, patients have come forth to call for their swift reimbursement.

The Korea Alliance of Patients Organizations delivered an opinion letter to HIRA last Tuesday, requesting that Roche's Polivy (polatuzumab vedotin) and BeiGene’s Brukinsa (zanubrutinib) be tabled on the Cancer Disease Review Committee and reviewed whether it is appropriate to reimburse them.

Read Korea Biomedical Review article